Lacticaseibacillus rhamnosus HN001 can promote the maturation of babies' intestinal defense system, modulates babies' gut microbiota and meanwhile alleviates bloating and abdominal pain caused by lactose intolerance.

Lactobacillus acidophilus NCFM, Bifidobacterium animalis subsp. lactis Bi-07 and BB-12 can activate NK immune cells by increasing the serum hemolysin antibody titer in subjects, thereby enhancing the body's immunity and delaying immune aging.

Bifidobacterium animalis subsp. lactis BB-12 and HN019, Lactobacillus acidophilus NCFM can significantly alleviate rotavirus- or antibiotic-induced diarrhea, promote intestinal motility and effectively relieve dry and hard stools and difficult bowel movements in constipated individuals.

Bifidobacterium breve M-16V can reduce IgE levels and restore Th1/Th2 balance so as to effectively improve symptons caused by protein allergy and atopic dermatitis in babies.

Bifidobacterium animalis subsp. lactis BB-12 can strengthen the gastrointestinal mucosal barrier by enhancing mucin expression so as to effectively reduce bacterial and viral infection risks and the incidence of common inflammatory symptoms in infants.

Bifidobacterium breve M-16V can enhance α-amylase activity so as to fully hydrolyze α-1,4-glycosidic bonds in the starch and increase the production of reducing sugars such as glucose, maltose, maltotriose, and dextrins, thereby promoting nutrient absorption.

Bifidobacterium animalis subsp. lactis BB-12 can effective reduce levels of Actinomyces, Chlorella, and Porphyromonas in saliva and dental plaque so as to maintain a healthy oral microbiota, promote gum health, and resist plaque formation.